img

Global Metastatic Ovarian Cancer Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Metastatic Ovarian Cancer Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Metastatic Ovarian Cancer Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Metastatic Ovarian Cancer Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinic and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Metastatic Ovarian Cancer Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Metastatic Ovarian Cancer Drug key manufacturers include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited and Northwest Biotherapeutics, Inc., etc. Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd. are top 3 players and held % sales share in total in 2022.
Metastatic Ovarian Cancer Drug can be divided into E-7449, Crizotinib, CMB-305 and G-305, etc. E-7449 is the mainstream product in the market, accounting for % sales share globally in 2022.
Metastatic Ovarian Cancer Drug is widely used in various fields, such as Clinic, Hospital and Others,, etc. Clinic provides greatest supports to the Metastatic Ovarian Cancer Drug industry development. In 2022, global % sales of Metastatic Ovarian Cancer Drug went into Clinic filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Metastatic Ovarian Cancer Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Segment by Type
E-7449
Crizotinib
CMB-305
G-305
LV-305
Others

Segment by Application


Clinic
Hospital
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Metastatic Ovarian Cancer Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Metastatic Ovarian Cancer Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Metastatic Ovarian Cancer Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Metastatic Ovarian Cancer Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Metastatic Ovarian Cancer Drug introduction, etc. Metastatic Ovarian Cancer Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Metastatic Ovarian Cancer Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Metastatic Ovarian Cancer Drug Market Overview
1.1 Metastatic Ovarian Cancer Drug Product Overview
1.2 Metastatic Ovarian Cancer Drug Market Segment by Type
1.2.1 E-7449
1.2.2 Crizotinib
1.2.3 CMB-305
1.2.4 G-305
1.2.5 LV-305
1.2.6 Others
1.3 Global Metastatic Ovarian Cancer Drug Market Size by Type
1.3.1 Global Metastatic Ovarian Cancer Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Metastatic Ovarian Cancer Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Metastatic Ovarian Cancer Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2018-2024)
2 Global Metastatic Ovarian Cancer Drug Market Competition by Company
2.1 Global Top Players by Metastatic Ovarian Cancer Drug Sales (2018-2024)
2.2 Global Top Players by Metastatic Ovarian Cancer Drug Revenue (2018-2024)
2.3 Global Top Players by Metastatic Ovarian Cancer Drug Price (2018-2024)
2.4 Global Top Manufacturers Metastatic Ovarian Cancer Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Metastatic Ovarian Cancer Drug Market Competitive Situation and Trends
2.5.1 Metastatic Ovarian Cancer Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Metastatic Ovarian Cancer Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Metastatic Ovarian Cancer Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Metastatic Ovarian Cancer Drug Market
2.8 Key Manufacturers Metastatic Ovarian Cancer Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Metastatic Ovarian Cancer Drug Status and Outlook by Region
3.1 Global Metastatic Ovarian Cancer Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Metastatic Ovarian Cancer Drug Historic Market Size by Region
3.2.1 Global Metastatic Ovarian Cancer Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Metastatic Ovarian Cancer Drug Sales in Value by Region (2018-2024)
3.2.3 Global Metastatic Ovarian Cancer Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Metastatic Ovarian Cancer Drug Forecasted Market Size by Region
3.3.1 Global Metastatic Ovarian Cancer Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Metastatic Ovarian Cancer Drug Sales in Value by Region (2024-2034)
3.3.3 Global Metastatic Ovarian Cancer Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Metastatic Ovarian Cancer Drug by Application
4.1 Metastatic Ovarian Cancer Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Metastatic Ovarian Cancer Drug Market Size by Application
4.2.1 Global Metastatic Ovarian Cancer Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Metastatic Ovarian Cancer Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Metastatic Ovarian Cancer Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2018-2024)
5 North America Metastatic Ovarian Cancer Drug by Country
5.1 North America Metastatic Ovarian Cancer Drug Historic Market Size by Country
5.1.1 North America Metastatic Ovarian Cancer Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Metastatic Ovarian Cancer Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Metastatic Ovarian Cancer Drug Sales in Value by Country (2018-2024)
5.2 North America Metastatic Ovarian Cancer Drug Forecasted Market Size by Country
5.2.1 North America Metastatic Ovarian Cancer Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Metastatic Ovarian Cancer Drug Sales in Value by Country (2024-2034)
6 Europe Metastatic Ovarian Cancer Drug by Country
6.1 Europe Metastatic Ovarian Cancer Drug Historic Market Size by Country
6.1.1 Europe Metastatic Ovarian Cancer Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Metastatic Ovarian Cancer Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Metastatic Ovarian Cancer Drug Sales in Value by Country (2018-2024)
6.2 Europe Metastatic Ovarian Cancer Drug Forecasted Market Size by Country
6.2.1 Europe Metastatic Ovarian Cancer Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Metastatic Ovarian Cancer Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Metastatic Ovarian Cancer Drug by Region
7.1 Asia-Pacific Metastatic Ovarian Cancer Drug Historic Market Size by Region
7.1.1 Asia-Pacific Metastatic Ovarian Cancer Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Metastatic Ovarian Cancer Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Metastatic Ovarian Cancer Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Metastatic Ovarian Cancer Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Metastatic Ovarian Cancer Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Metastatic Ovarian Cancer Drug Sales in Value by Region (2024-2034)
8 Latin America Metastatic Ovarian Cancer Drug by Country
8.1 Latin America Metastatic Ovarian Cancer Drug Historic Market Size by Country
8.1.1 Latin America Metastatic Ovarian Cancer Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Metastatic Ovarian Cancer Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Metastatic Ovarian Cancer Drug Sales in Value by Country (2018-2024)
8.2 Latin America Metastatic Ovarian Cancer Drug Forecasted Market Size by Country
8.2.1 Latin America Metastatic Ovarian Cancer Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Metastatic Ovarian Cancer Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Metastatic Ovarian Cancer Drug by Country
9.1 Middle East and Africa Metastatic Ovarian Cancer Drug Historic Market Size by Country
9.1.1 Middle East and Africa Metastatic Ovarian Cancer Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Metastatic Ovarian Cancer Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Metastatic Ovarian Cancer Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Metastatic Ovarian Cancer Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Metastatic Ovarian Cancer Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Metastatic Ovarian Cancer Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Adgero Biopharmaceuticals Inc
10.1.1 Adgero Biopharmaceuticals Inc Company Information
10.1.2 Adgero Biopharmaceuticals Inc Introduction and Business Overview
10.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
10.1.5 Adgero Biopharmaceuticals Inc Recent Development
10.2 Cellceutix Corporation
10.2.1 Cellceutix Corporation Company Information
10.2.2 Cellceutix Corporation Introduction and Business Overview
10.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Products Offered
10.2.5 Cellceutix Corporation Recent Development
10.3 Eisai Co., Ltd.
10.3.1 Eisai Co., Ltd. Company Information
10.3.2 Eisai Co., Ltd. Introduction and Business Overview
10.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
10.3.5 Eisai Co., Ltd. Recent Development
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 F. Hoffmann-La Roche Ltd. Company Information
10.4.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview
10.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Products Offered
10.4.5 F. Hoffmann-La Roche Ltd. Recent Development
10.5 Immune Design Corp.
10.5.1 Immune Design Corp. Company Information
10.5.2 Immune Design Corp. Introduction and Business Overview
10.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Products Offered
10.5.5 Immune Design Corp. Recent Development
10.6 Millennium Pharmaceuticals Inc
10.6.1 Millennium Pharmaceuticals Inc Company Information
10.6.2 Millennium Pharmaceuticals Inc Introduction and Business Overview
10.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
10.6.5 Millennium Pharmaceuticals Inc Recent Development
10.7 MolMed S.p.A.
10.7.1 MolMed S.p.A. Company Information
10.7.2 MolMed S.p.A. Introduction and Business Overview
10.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Products Offered
10.7.5 MolMed S.p.A. Recent Development
10.8 Natco Pharma Limited
10.8.1 Natco Pharma Limited Company Information
10.8.2 Natco Pharma Limited Introduction and Business Overview
10.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Products Offered
10.8.5 Natco Pharma Limited Recent Development
10.9 Northwest Biotherapeutics, Inc.
10.9.1 Northwest Biotherapeutics, Inc. Company Information
10.9.2 Northwest Biotherapeutics, Inc. Introduction and Business Overview
10.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Products Offered
10.9.5 Northwest Biotherapeutics, Inc. Recent Development
10.10 Pfizer Inc.
10.10.1 Pfizer Inc. Company Information
10.10.2 Pfizer Inc. Introduction and Business Overview
10.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Products Offered
10.10.5 Pfizer Inc. Recent Development
10.11 Richter Gedeon Nyrt.
10.11.1 Richter Gedeon Nyrt. Company Information
10.11.2 Richter Gedeon Nyrt. Introduction and Business Overview
10.11.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Products Offered
10.11.5 Richter Gedeon Nyrt. Recent Development
10.12 Sumitomo Dainippon Pharma Co., Ltd.
10.12.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
10.12.2 Sumitomo Dainippon Pharma Co., Ltd. Introduction and Business Overview
10.12.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
10.12.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Development
10.13 VG Life Sciences, Inc.
10.13.1 VG Life Sciences, Inc. Company Information
10.13.2 VG Life Sciences, Inc. Introduction and Business Overview
10.13.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2018-2024)
10.13.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Products Offered
10.13.5 VG Life Sciences, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Metastatic Ovarian Cancer Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Metastatic Ovarian Cancer Drug Industrial Chain Analysis
11.4 Metastatic Ovarian Cancer Drug Market Dynamics
11.4.1 Metastatic Ovarian Cancer Drug Industry Trends
11.4.2 Metastatic Ovarian Cancer Drug Market Drivers
11.4.3 Metastatic Ovarian Cancer Drug Market Challenges
11.4.4 Metastatic Ovarian Cancer Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Metastatic Ovarian Cancer Drug Distributors
12.3 Metastatic Ovarian Cancer Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of E-7449
Table 2. Major Company of Crizotinib
Table 3. Major Company of CMB-305
Table 4. Major Company of G-305
Table 5. Major Company of LV-305
Table 6. Major Company of Others
Table 7. Global Metastatic Ovarian Cancer Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Metastatic Ovarian Cancer Drug Market Share in Value by Type (2018-2024)
Table 12. Global Metastatic Ovarian Cancer Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Metastatic Ovarian Cancer Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Metastatic Ovarian Cancer Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Metastatic Ovarian Cancer Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Metastatic Ovarian Cancer Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Metastatic Ovarian Cancer Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Metastatic Ovarian Cancer Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Metastatic Ovarian Cancer Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Metastatic Ovarian Cancer Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Metastatic Ovarian Cancer Drug Sales Share by Company (2018-2024)
Table 30. Global Metastatic Ovarian Cancer Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Metastatic Ovarian Cancer Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Metastatic Ovarian Cancer Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Metastatic Ovarian Cancer Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Metastatic Ovarian Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Metastatic Ovarian Cancer Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Metastatic Ovarian Cancer Drug Market
Table 37. Key Manufacturers Metastatic Ovarian Cancer Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Metastatic Ovarian Cancer Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Metastatic Ovarian Cancer Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Metastatic Ovarian Cancer Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Metastatic Ovarian Cancer Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Metastatic Ovarian Cancer Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Metastatic Ovarian Cancer Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Metastatic Ovarian Cancer Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Metastatic Ovarian Cancer Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Metastatic Ovarian Cancer Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Metastatic Ovarian Cancer Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Metastatic Ovarian Cancer Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Metastatic Ovarian Cancer Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Metastatic Ovarian Cancer Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Value by Country (2024-2034)
Table 111. Adgero Biopharmaceuticals Inc Company Information
Table 112. Adgero Biopharmaceuticals Inc Introduction and Business Overview
Table 113. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product
Table 115. Adgero Biopharmaceuticals Inc Recent Development
Table 116. Cellceutix Corporation Company Information
Table 117. Cellceutix Corporation Introduction and Business Overview
Table 118. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product
Table 120. Cellceutix Corporation Recent Development
Table 121. Eisai Co., Ltd. Company Information
Table 122. Eisai Co., Ltd. Introduction and Business Overview
Table 123. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product
Table 125. Eisai Co., Ltd. Recent Development
Table 126. F. Hoffmann-La Roche Ltd. Company Information
Table 127. F. Hoffmann-La Roche Ltd. Introduction and Business Overview
Table 128. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product
Table 130. F. Hoffmann-La Roche Ltd. Recent Development
Table 131. Immune Design Corp. Company Information
Table 132. Immune Design Corp. Introduction and Business Overview
Table 133. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Immune Design Corp. Metastatic Ovarian Cancer Drug Product
Table 135. Immune Design Corp. Recent Development
Table 136. Millennium Pharmaceuticals Inc Company Information
Table 137. Millennium Pharmaceuticals Inc Introduction and Business Overview
Table 138. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product
Table 140. Millennium Pharmaceuticals Inc Recent Development
Table 141. MolMed S.p.A. Company Information
Table 142. MolMed S.p.A. Introduction and Business Overview
Table 143. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product
Table 145. MolMed S.p.A. Recent Development
Table 146. Natco Pharma Limited Company Information
Table 147. Natco Pharma Limited Introduction and Business Overview
Table 148. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product
Table 150. Natco Pharma Limited Recent Development
Table 151. Northwest Biotherapeutics, Inc. Company Information
Table 152. Northwest Biotherapeutics, Inc. Introduction and Business Overview
Table 153. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 154. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product
Table 155. Northwest Biotherapeutics, Inc. Recent Development
Table 156. Pfizer Inc. Company Information
Table 157. Pfizer Inc. Introduction and Business Overview
Table 158. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 159. Pfizer Inc. Metastatic Ovarian Cancer Drug Product
Table 160. Pfizer Inc. Recent Development
Table 161. Richter Gedeon Nyrt. Company Information
Table 162. Richter Gedeon Nyrt. Introduction and Business Overview
Table 163. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 164. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product
Table 165. Richter Gedeon Nyrt. Recent Development
Table 166. Sumitomo Dainippon Pharma Co., Ltd. Company Information
Table 167. Sumitomo Dainippon Pharma Co., Ltd. Introduction and Business Overview
Table 168. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 169. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product
Table 170. Sumitomo Dainippon Pharma Co., Ltd. Recent Development
Table 171. VG Life Sciences, Inc. Company Information
Table 172. VG Life Sciences, Inc. Introduction and Business Overview
Table 173. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 174. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product
Table 175. VG Life Sciences, Inc. Recent Development
Table 176. Key Raw Materials Lists
Table 177. Raw Materials Key Suppliers Lists
Table 178. Metastatic Ovarian Cancer Drug Market Trends
Table 179. Metastatic Ovarian Cancer Drug Market Drivers
Table 180. Metastatic Ovarian Cancer Drug Market Challenges
Table 181. Metastatic Ovarian Cancer Drug Market Restraints
Table 182. Metastatic Ovarian Cancer Drug Distributors List
Table 183. Metastatic Ovarian Cancer Drug Downstream Customers
Table 184. Research Programs/Design for This Report
Table 185. Key Data Information from Secondary Sources
Table 186. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Ovarian Cancer Drug Product Picture
Figure 2. Global Metastatic Ovarian Cancer Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Metastatic Ovarian Cancer Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Metastatic Ovarian Cancer Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of E-7449
Figure 6. Global E-7449 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Crizotinib
Figure 8. Global Crizotinib Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of CMB-305
Figure 10. Global CMB-305 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of G-305
Figure 12. Global G-305 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of LV-305
Figure 14. Global LV-305 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Metastatic Ovarian Cancer Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Metastatic Ovarian Cancer Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Metastatic Ovarian Cancer Drug Revenue in 2022
Figure 31. Metastatic Ovarian Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Clinic
Figure 33. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Hospital
Figure 35. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Metastatic Ovarian Cancer Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Metastatic Ovarian Cancer Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Metastatic Ovarian Cancer Drug Manufacturing Cost Structure
Figure 51. Metastatic Ovarian Cancer Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries